Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C21 InvestmentsCXXIF 31 EV-to-EBIT is 79.83 as of Sep. 02, 2026, which is 1658% above its 10-year median of 4.54. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 683 Drug Manufacturers companies, C21 Investments ranks worse than 91.65% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
C21 Investments's Enterprise Value for the quarter that ended in Jun. 2026 was $35.31 Mil.
C21 Investments's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments EV-to-EBIT Related Terms
C21 Investments EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for C21 Investments's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where C21 Investments's EV-to-EBIT falls into.
C21 Investments's current Enterprise Value is $41.35 Mil.
C21 Investments's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a EV-to-EBIT of 79.83 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on C21 Investments and its competitors. This is 1658% above median its historical median of 4.54. According to the industry distribution chart, C21 Investments ranks #626 out of 683 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is C21 Investments' EV-to-EBIT too high?
C21 Investments' current EV-to-EBIT of 79.83 is 1658% above median its 10-year median of 4.54. The Drug Manufacturers industry median EV-to-EBIT is 16.09. C21 Investments' value of 79.83 is 396.1% above this industry median. Based on the distribution chart, C21 Investments ranks #626 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #626 out of 683 companies for EV-to-EBIT. This places C21 Investments in the lower half of its industry. The industry median EV-to-EBIT is 16.09. C21 Investments' value of 79.83 is 396.1% above this benchmark. While the company's 10-year median is 4.54 vs. the industry median of 16.09, C21 Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.09, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current EV-to-EBIT of 79.83 is 396.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current EV-to-EBIT is 79.83, which is 1658% above median its own 10-year median of 4.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.27, compared to a current price of $0.26 — trading 2% below its estimated fair value. The current EV-to-EBIT is 79.83, which is 1658% above median its 10-year median of 4.54 and 396.1% above the Drug Manufacturers industry median of 16.09. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For C21 Investments (CXXIF), the current EV-to-EBIT is 79.83 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.26 is trading 2% below its estimated GF Value™ of $0.27.
GuruFocus considers C21 Investments to be Fairly Valued.
Key valuation signals for CXXIF:
EV-to-EBIT: 79.83 (1658% above median its 10-year median of 4.54)
GF Value™: $0.27 vs. price of $0.26 (2% below fair value)
Industry Position: 396.1% above the Drug Manufacturers median (#626 of 683)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
